Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, PhD; and Sarah Sammons, MD, discuss the use of oral SERD-based therapy in the treatment of HR+/HER2– metastatic breast cancer through a series of clinical cases.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Implement best practices for molecular testing in HR+/HER2-negative metastatic breast cancer, including selection of tissue vs liquid biopsy and indications for repeat testing at progression
• Differentiate between available and emerging oral SERDs based on pivotal trial data, real-world evidence, and patient-specific factors to guide treatment selection in ESR1-mutant disease
• Evaluate the role of oral SERD monotherapy vs combination regimens in the post-CDK4/6 inhibitor setting, balancing efficacy with tolerability
• Develop individualized treatment strategies for patients with co-occurring ESR1 and PIK3CA mutations, integrating evidence for oral SERDs and PI3K/AKT pathway inhibitors

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.

Chair:

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Cancer Program
UT Health San Antonio
The University of Texas MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant/Research Support: Eisai; Consultant: AstraZeneca, Genentech, Gilead, Lilly, The Menarini Group, Pfizer; Speaker: AstraZeneca, Daiichi Sankyo, Gilead.

Faculty:

Antonio Giordano, MD, PhD

Assistant Professor of Medicine and Senior Physician
Harvard Medical School
Clinical Director, Center for Cancer Therapeutic Innovation (Early Drug Development)
Medical Director, Breast Cancer Pathway
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Araris, AstraZeneca, Axis, Curio, DAVA, Lilly, Guardant Health, MDEducation, Novartis, Pfizer, Totus Medicine; Grant/Research Funding: Cardiff Oncology

Nadia Harbeck, MD, PhD

Chair, Conservative Oncology
Director, Breast Center
LMU University Hospital
Munich, Germany

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Daiichi-Sankyo, IQVIA, Novartis, Pfizer, Roche/Genentech; Speaker Bureau: Amgen, AstraZeneca, Daiichi-Sankyo, Exact Sciences, Lilly, Menarini-Stemline, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Viatris, Zuellig Pharma; Grant/Research Funding (paid to institution): AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche/Genentech; Stock/Ownership: WSG (Women’s Cancer Study Group)

Sarah Sammons, MD

Co-Chief of Breast Oncology
University of Maryland
Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, MD

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, Pfizer, Relay Therapeutics, Seagen; Grant/Research Funding: Alterome, AstraZeneca, BioNTech, Daiichi Sankyo, Iambic, Lilly, Relay Therapeutics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including additional panel discussion, go tohttps://www.gotoper.com/courses/cases-and-conversations-optimizing-oral-serd-based-therapy-after-cdk46-inhibition-in-hrher2-mbc-xv6m.

Release Date

July 14, 2026

Expiration Date

July 14, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.